BACKGROUND: Generalized pustular psoriasis (GPP), a rare and recurrent autoinflammatory disease, imposes a substantial burden on patients and society. Awareness of GPP in China remains limited. METHODS: This cross-sectional survey, conducted between September 2021 and May 2023 across 14 hospitals in China, included GPP patients of all ages and disease phases. Data collected encompassed demographics, clinical characteristics, economic impact, disease severity, quality of life, and treatment-related complications. Risk factors for GPP recurrence were analyzed. RESULTS: Among 127 patients (female/male ratio = 1.35:1), the mean age of disease onset was 25 years (1st quartile [Q1]-3rd quartile [Q3]: 11-44 years); 29.2% had experienced GPP for more than 10 years. Recurrence occurred in 75.6% of patients, and nearly half reported no identifiable triggers. Younger age at disease onset ( P  = 0.021) and transitioning to plaque psoriasis ( P  = 0.022) were associated with higher recurrence rates. The median diagnostic delay was 8 months (Q1-Q3: 2-41 months), and 32.3% of patients reported misdiagnoses. Comorbidities were present in 53.5% of patients, whereas 51.1% experienced systemic complications during treatment. Depression and anxiety affected 84.5% and 95.6% of patients, respectively. During GPP flares, the median Dermatology Life Quality Index score was 19.0 (Q1-Q3: 13.0-23.5). This score showed significant differences between patients with and without systemic symptoms; it demonstrated correlations with both depression and anxiety scores. Treatment costs caused financial hardship in 55.9% of patients, underscoring the burden associated with GPP. CONCLUSIONS The substantial disease and economic burdens among Chinese GPP patients warrant increased attention. Patients with early onset disease and those transitioning to plaque psoriasis require targeted interventions to mitigate the high recurrence risk.
Humans ; Male ; Female ; Psoriasis/pathology* ; Adult ; Cross-Sectional Studies ; Adolescent ; Child ; Young Adult ; Quality of Life ; Middle Aged ; China/epidemiology* ; Recurrence ; Risk Factors ; Surveys and Questionnaires ; East Asian People

Objective:To explore clinical therapeutic effect and safety of diltiazem treating coronary artery spasm. Methods:A total of 100 patients with coronary artery spasm were selected in our hospital.According to number ta-ble method,they were randomly and equally divided into routine treatment group (n=50,received,lipid regulation and expanding coronory artery etc.)and diltiazem group (n=50,received diltiazem pumping based on routine treat-ment).Clinical and ECG therapeutic effect,changes of blood lipids,nitric oxide (NO)and endothelin-1 (ET-1) levels before and after treatment and safety were compared between two groups.Results:(1 )Compared with rou-tine treatment group,there were significant increase in total effective rates of clinical effect (60.00% vs.94.00%) and ECG (62.00% vs.92.00%)in diltiazem group,P<0.01 both;(2)Compared with before treatment,there were significant improvements in all ECG indexes,heart rate and blood pressure in two groups after treatment,and those of diltiazem group were significantly better than those of routine treatment group (P<0.05 all);(3)Com-pared with before treatment and routine treatment group,there were significant improvements in blood lipid levels in diltiazem group after treatment (P<0.05 all);(4)Compared with before treatment and routine treatment group,there was significant rise in NO level [(95.17±19.99)μmol/L,(95.17±21.22)μmol/L vs.(106.71± 22.38)μmol/L]and significant reduction in ET-1 level [(64.09±16.29)ng/L,(59.98±14.28)ng/L vs.(44.91± 6.38)ng/L]in diltiazem group after treatment (P<0.05 all);(6)During treatment,there were no adverse reac-tion in both groups.Conclusion:Diltiazem based on routine medication possess significant therapeutic effect and high safety for treating coronary artery spasm,which is worth extension in clinic.